Dexamethasone Shows Potential Of Repurposed Generics Against COVID-19
Repurposing Existing Medicines Is Key Part Of Pandemic Solution, Industry Insists
Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.
You may also be interested in...
REMEDi4ALL is the latest in a series of European initiatives to develop and centralize drug repurposing R&D. The group will identify, test and validate new indications for existing medicines on top of shaping policies favorable to repurposing.
Savings made through the use of generics and biosimilars have been highlighted by the UK’s NHS, with the organization pointing to savings of £1.2bn over three years, a third of which came from Humira biosimilars alone.
Earlier industry involvement in repurposing activities and a more tailored European regulatory environment for value added medicines are among the proposals set out in a new report published by Medicines for Europe. The association has also suggested creating an “indications pool” to act as a central repository for repurposing information generated by not-for-profit and academic organizations through a STAMP pilot project.